Drug prices
8 articles
Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain
Myths and facts
Gilead’s license is a fool’s bargain that inhibits access for nearly half the world’s HCV population. More
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries
By Karyn Kaplan
A report, developed by TAG, presents a number of key strategies through real-world case studies and shows how HIV-targeted strategies can be adapted to increase HCV treatment access. More
The Potential Impact of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership on Thailand’s Hepatitis C Treatment Program
Acceding to trade agreements such as the CPTPP that require increasing intellectual property protection, could compromise Thailand’s hepatitis C program and other national treatment programs reliant on affordable generic medicines. More
